NCT02639832View on ClinicalTrials.gov

A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.

UnknownOBSERVATIONAL
Enrollment

210

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2019

Conditions
Triple Negative Breast CancerNatural Killer CellsBRCA Mutation
Interventions
DEVICE

LiquidBiopsy®, NK VueTM

The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.

Trial Locations (1)

91361

Cynvenio Biosystems, Inc., Westlake Village

Sponsors
All Listed Sponsors
lead

Cynvenio Biosystems

INDUSTRY

NCT02639832 - A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation. | Biotech Hunter | Biotech Hunter